Cellectis pivots to in vivo gene editing, restructures operations to extend cash runway into H2 2028

• Cellectis will reorganize to pivot from cell therapy development to an in vivo gene-editing strategy focused on chronic diseases.
• Two lead programs, HEAL-101 and HEAL-201, will advance toward Phase 1 investigator-initiated trials in China.
• Development of lasme-cel and eti-cel will end, with partnering pursued, reflecting a weaker outlook for B-ALL and NHL opportunities.
• Operations will be resized to support the new pipeline while maintaining existing cell therapy partnerships with AstraZeneca, Allogene, Servier, Iovance.
• Cost actions aim to extend cash runway into H2 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140240OMX_____CNEWS_EN_GNW9825815_en) on September 14, 2026, and is solely responsible for the information contained therein.